Home
Industry Reports
Pharmaceuticals and Healthcare

Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program

Published: Apr-2012 Report Code: GBIHC194MR Report Format: Electronic PDF

Description

Inquire Before Buying

GBI Research, the leading business intelligence provider, has released its latest research “Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement of Costly Drugs Through the DLO’s Seven Nosologies Program”. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Russia, with key data, information and analysis of the steps of the pricing and reimbursement process. The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement in Russia due to the implementation of a new law “On Circulation of Drugs”. The scenario of pricing and reimbursement of drugs in Russia is in a dynamic phase. The government of Russia increased the funding of National Healthcare Project to improve the primary healthcare provided to Russians. Under the National Healthcare Project, improvement in primary healthcare, out-patient clinics and technology centers was done. The launch of the DLO (the acronym for Additional Medicines Supply Program) program was done for disabled persons, pensioners and patients in need of specialized medicines. It was estimated by the Ministry of Health and Social Development that 15 million people will be covered under this program. Since the option of opting for money instead of medicine was provided under the program, a greater number of patients opted for the money. Those patients who opted for medicines got a chance to be treated by some of the best medicines available for their respective therapy areas. The VZN program (acronym for Seven Nosologies Program) was segmented from the DLO. This was because there is a set of people who need specialized medicines which are particularly expensive. The other segment of the DLO program is called the Essential Drug Program (ONLS). Compulsory medical insurance for all Russians was introduced in 1995. Under the medical insurance plan Russians recieve treatment, hospitalization, surgical operation, dental care and other facilities free of charge. However, state medical insurance does not seem to be sufficient for all Russians, so private insurance (voluntary medical insurance) players are also active in the field. The implementation of the new law “on circulation of drugs” resulted in the mandatory registration of prices of drugs listed in the Essential Drug List (EDL) in Russia. This means that the Russian government will now regulate the prices of drugs more uniformly. The decision of the Russian government to boost the domestic pharmaceutical market will lead to the launch of more innovative drugs by domestic pharmaceutical companies. Many major global pharmaceutical companies are initiating and expanding their production capacities in Russia to penetrate further into this market.

Scope

Detailed study of the healthcare scenario in the Russia.
Analysis of the pricing and reimbursement mechanisms in Russia.
Key changes that follow from the implementation of new law “on circulation of drugs” in the pricing and reimbursement system.
Details about government bodies which regulate different processes of pricing and reimbursement in Russia.
Details about share of major companies in reimbursement program of Russia.
Insight into various reimbursement programs in Russia.

Reasons to Buy

Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in Russia.
Optimize your investment through identification and understanding of the changes in the pharmaceutical regulatory mechanism in Russia.
Knowledge about the regulatory bodies who undertake different processes of price registration.
Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene in Russia.
Negotiate better with the government agencies to maximize reimbursement on the drugs by understanding the mechanism.

Related Industry Reports

License Details

Single User License:

$3,500.00

Site License:

$7,000.00

Global License:

$10,500.00

Search Help
To run a quick Search on GBI Research site, enter the keywords for which you wish to search. By default, quick search will return documents which have at least any one of the words you have queried (an automatic "Or" search).

Detailed Functionality
• Higher relevance will be given to those documents where your search terms appear a greater number of times. Avoid using words such "and" or "or".

Phrase Searches
• You can search for a phrase by typing the keywords in quotation marks (""). For example, typing "Global Energy Efficient Lighting" will only return documents that contain this exact phrase.

Or Queries
• By default, search returns documents that include any of your search terms. There is no need to include or between terms. The order in which the terms are typed will affect the search results.

And Queries
• Adding and between two search terms means the search will return documents including both terms, whether they are listed together or not.


	Electronic PDF copy delivered via email. Report can be used by individual purchaser only.


	Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.


	Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.